Galderma has a new leadership team. The company, which has its North American headquarters in Fort Worth, Texas, is planning for growth with its upcoming key product launches over the next few months.  

“Galderma’s single focus on dermatology and unique holistic view of skin health distinguish it in the marketplace and position the company to substantially increase its share of the dermatology and aesthetic medicine markets,” said Stuart Raetzman, newly appointed Global CEO of Galderma Pharma S.A., reporting to Humberto C. Antunes, Chairman of Galderma Pharma S.A. and CEO of Nestle Skin Health S.A.

In addition to Raetzman, Galderama’s leadership team includes:

Todd Zavodnick, former Vice President and General Manager for the Aesthetic and Corrective business, has been appointed President and General Manager of Galderma Laboratories; Safia Rizvi is Vice President and General Manager of U.S. Prescription Business Unit; Miles Harrison has been named Vice President and General Manager U.S. Self-Medication Business; and Dr. Philip Brown MD, JD, continues to serve as Senior Vice President of Medical and Regulatory Affairs.

Galderma’s Prescription Business Unit will focus on pharmaceutical products available by prescription and promoted almost exclusively to health care professionals.
The Self-Medication Business Unit includes non-prescription, cosmetic and over-the-counter drug brands. These products include the iconic brand Cetaphil (cleansers and moisturizers), and Cetaphil Baby, the most recent addition to the line. Galderma’s first over-the-counter acne regimen, Benzac Acne Solutions, was launched on January 5th. In addition, several new, highly differentiated products will be launched in 2015.

The Aesthetic & Corrective Business Unit includes a broad portfolio of first class products and services for minimally invasive cosmetic treatments. Galderma is a global leader in Aesthetic medicine with two decades of expertise and 20 million Restylane treatments received by patients.

“Innovation capacity, comprehensive portfolio of premium quality products and long-lasting commitment to serving doctors and patients mark the reputation of Galderma. With this reorganization, our customers will see that all the reasons they value and trust Galderma will remain unchanged, while our ambitions and product lines are growing simultaneously in three business channels to meet even greater skin health needs,” said Todd Zavodnick, president and general manager of Galderma Laboratories.

Humberto C. Antunes, newly appointed CEO of Nestle Skin Health, added, “Our goal is to grow the number of people the company serves to over a billion within 10 years by offering skin health solutions that primarily maintain, nourish and enhance and if needed, treat, correct and restore the skin to its healthy state. Solutions that really work for either healthy or compromised skin contribute to the overall health and quality of people’s lives immeasurably – and that’s what we do.”

Photo: Todd Zavodnick, President and GM of Galderma Laboratories, L.P.; Safia Rizvi, VP and GM, U.S. Prescription Business Unit; Miles Harrison, VP and GM, U.S. Self-Medication Business Unit; Dr. Philip Brown MD, JD, Senior VP, Medical and Regulatory